Overview

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Gary Morrow
Collaborator:
National Cancer Institute (NCI)
Treatments:
Dalteparin
Gemcitabine
Heparin, Low-Molecular-Weight
Tinzaparin